Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer's disease.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26892305.
- Also identified by DOI 10.1038/ncomms10759 and PMC identifier 4762893.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Owing to their specificity and high-affinity binding, monoclonal antibodies have potential as positron emission tomography (PET) radioligands and are currently used to image various targets in peripheral organs. However, in the central nervous system, antibody uptake is limited by the blood-brain barrier (BBB). Here we present a PET ligand to be used for diagnosis and evaluation of treatment effects in Alzheimer's disease. The amyloid β (Aβ) antibody mAb158 is radiolabelled and conjugated to a transferrin receptor antibody to enable receptor-mediated transcytosis across the BBB. PET imaging of two different mouse models with Aβ pathology clearly visualize Aβ in the brain. The PET signal increases with age and correlates closely with brain Aβ levels. Thus, we demonstrate that antibody-based PET ligands can be successfully used for brain imaging.
Medical subject headings
- Alzheimer Disease
- Amyloid beta-Peptides
- Brain
- Positron-Emission Tomography